To the authors' knowledge, little is known regarding the relationship between patients' and families' satisfaction with aggressive end-of-life care. Herein, the authors examined the associations between episodes of aggressive care (ie, chemotherapy, mechanical ventilation, acute hospitalizations, and intensive care unit admissions) within the last 30 days of life and families' evaluations of end-of-life care among patients with non-small cell lung cancer (NSCLC). METHODS: A total of 847 patients with NSCLC (34% of whom were aged <65 years) who died in a nursing home or intensive care, acute care, or hospice/palliative care (HPC) unit at 1 of 128 Veterans Affairs Medical Centers between 2010 and 2012 were examined. Data sources included Veterans Affairs administrative and clinical data, Medicare claims, and the Bereaved Family Survey. The response rate for the Bereaved Family Survey was 62%. RESULTS: Greater than 72% of veterans with advanced lung cancer who died in an inpatient setting had at least 1 episode of aggressive care and 31% received chemotherapy within the last 30 days of life. For all units except for HPC, when patients experienced at least 1 episode of aggressive care, bereaved families rated care lower compared with when patients did not receive any aggressive care. For patients dying in an HPC unit, the associations between overall ratings of care and 2 inpatient admissions or any episode of aggressive care were not found to be statistically significant. Rates of aggressive care were not associated with age, and family ratings of care were similar for younger and older patients. CONCLUSIONS: Aggressive care within the last month of life is common among patients with NSCLC and is associated with lower family evaluations of end-of-life care. Specialized care provided within an HPC unit may mitigate the negative effects of aggressive care on these outcomes. Cancer 2017;123:3186-94. V C 2017 American Cancer Society.
INTRODUCTION
Aggressive, potentially burdensome, care at the end of life is commonplace for patients with advanced cancer. A recent study of end-of-life cancer care in 7 developed countries documented that within the last 30 days of life, approximately 52% of older Americans with cancer were admitted to an acute care hospital, 27% had at least 1 admission to an intensive care unit (ICU), and >10% received chemotherapy. 1 Overall hospitalization rates in the last 30 days of life ranged from 44% to 64% across the 7 countries, with 6% to 16% of older patients with cancer receiving chemotherapy within the last month of life. 1 There also is evidence that rates of aggressive care at the end of life have increased over time. [2] [3] [4] [5] [6] These trends are concerning given the evidence demonstrating that aggressive treatments do not prolong survival, 7, 8 and are not associated with a better quality of life. 4, 7, 9, 10 To the best of our knowledge, 2 studies to date have examined aggressive cancer therapies at the end of life within the Department of Veterans Affairs (VA). Keating et al 11 compared the aggressiveness of end-of-life cancer therapy in matched cohorts of VA patients and Medicare beneficiaries. They found that VA patients were significantly less likely than Medicare beneficiaries to receive chemotherapy within the last 30 days of life, to be admitted to an ICU, or to present to an emergency department within the last 30 days of life. Examining trends over time, Gonsalves et al 6 reported that the use of aggressive treatments within the last 30 days of life for patients with advanced cancer at one Midwestern VA medical center increased significantly from 2002 through 2008, despite the introduction of a palliative care service during this period.
The VA provides a unique window on cancer care processes and outcomes in that there are palliative care consult teams at every VA inpatient facility and dedicated inpatient hospice/palliative care units at >60% of these facilities. Moreover, the VA allows veterans to access curative therapies while receiving hospice/palliative care (ie, concurrent care). 12, 13 Finally, since 2010, the VA has elicited bereaved families' evaluations of care within the last month of life for nearly all veterans dying in all inpatient VA facilities across the United States and Puerto Rico. This population-based quality improvement program allows the VA to examine patient, family, and health care system factors that affect patient and family experiences of care. [14] [15] [16] [17] [18] [19] Bereaved families' assessments of care are a widely accepted approach to measuring outcomes of care at the end of life. [20] [21] [22] [23] However, to the best of our knowledge, few studies to date have examined families' evaluations of end-of-life care for patients with advanced cancer who receive aggressive care. An exception is a study by Wright et al 24 that examined the relation between aggressive care and bereaved families' evaluations of end-of-life care in a large sample of older adults who died of either colorectal or lung cancer. They found that families were significantly less likely to rate the care delivered at the last health care setting as "excellent" if the patient had had an ICU admission within the last 30 days of life or if the patient died in a hospital. In contrast, there was no relation found between families' ratings of end-of-life care and emergency department visits, multiple hospitalizations within the last month of life, or the receipt of chemotherapy during the final 2 weeks of life.
The purpose of the current study was to examine the relationships between aggressive care within the last 30 days of life and bereaved families' evaluations of end-oflife care for veterans with non-small cell lung cancer (NSCLC) who died in an acute care unit or ICU in VA hospitals, VA inpatient hospice/palliative care units, or VA nursing homes. Because the VA's investment in palliative care has resulted in a high percentage of inpatient deaths occurring in hospice/palliative care units, we also examined the moderating effects of admission to a hospice/palliative care unit on the families' evaluation of care for veterans treated with and without aggressive care. Finally, we also examined potential differences in the use and outcomes of aggressive care between younger and older veterans because to our knowledge the majority of previous studies excluded individuals aged <65 years. 1, 24 
MATERIALS AND METHODS

Sample
This retrospective observational study included veterans who were diagnosed from 2010 to 2011 with American Joint Committee on Cancer (AJCC) stage IV NSCLC who were identified using the VA tumor registry and died in a VA inpatient facility (acute care unit, ICU, nursing home, or hospice/palliative care unit) between 2010 and 2012 and whose next of kin completed the Bereaved Family Survey (BFS). The exclusion of veterans who died outside of a VA facility was necessary because at the time of the study, the BFS was administered only to bereaved families of veterans who died as inpatients, which included all deaths in the acute care unit/ICU, hospice/palliative care unit, and nursing homes. Decedents received care in 1 of 128 VA facilities across the VA system. 13 Human subjects approval for this analysis was obtained from the Providence VA Medical Center Institutional Review Board.
Data Sources
Independent variables: indicators of aggressive care
We measured aggressive care using 5 variables. These variables reflected our definition of aggressive care as either a potentially burdensome treatment or transition in the care setting occurring within the last 30 days of life that is associated with a lower quality of life or satisfaction with endof-life care. 7, 9, 25 Specifically, we measured the receipt of 1 or 2 of the following potentially burdensome treatments: 1) injectable chemotherapy or 2) mechanical ventilation within the last 30 days of life. Similar to earlier studies, 4, 24 we defined burdensome transitions in the care setting as 2 acute inpatient admissions (not to a nursing home or hospice/palliative care unit) or any ICU admission. We also determined whether the veteran had any episode of aggressive care, which we defined as having 1 of the treatments or transitions listed above.
We identified acute hospital and ICU admissions from 3 sources: VA inpatient claims, Medicare fee-forservice inpatient claims, and the VA Fee Basis Claims System. For ICU admissions, we used bed section codes for VA hospitalizations and revenue center codes for Medicarerelated hospitalizations. We identified aggressive care using 20, 26 For the current analysis, we used 2 validated BFS-derived measures. The first was the National Quality Forum-endorsed BFS Performance Measure (BFS-PM), 27 which is based on a single item for which respondents provide a global rating of care within the last month of life. 26 The BFS-PM score was calculated by dichotomizing the 5-point Likert scale into "excellent" versus all other responses (ie, very good, good, fair, and poor). Scores reflect the percentage of respondents who answered "excellent" for the global item.
The second outcome was the BFS Respectful Care and Communication factor score, which is 1 of 3 BFS factors identified using principal components analysis of the BFS polychoric correlation matrix. The use of polychoric correlations was necessary because of the nonnormal distribution of the BFS items. 28 The other 2 factors are Emotional/Spiritual Support and Death Benefits. We used the Respectful Care and Communication factor herein because it was the most germane to this analysis. The Respectful Care and Communication factor consists of 5 items: 1) staff listened to concerns; 2) staff gave treatment that the veteran wanted; 3) staff were kind, caring, and respectful; 4) staff kept family members informed about the veteran's condition and treatment; and 5) staff attended to personal care needs. Factor scores are calculated as the sum of the 5 items, resulting in a possible range of 0 to 15, with higher scores indicating better care and communication. 28 As noted earlier, outcomes were collected by the VA's Veteran Experience Center (VEC). During the study period, the BFS was administered predominantly as a telephone survey, using a standard protocol. Approximately 4 weeks after the patient's death, the VEC sent potential respondents a letter that described the survey and provided a toll-free telephone number that they could use to opt out. Beginning approximately 2 weeks later, trained interviewers made up to 3 attempts to contact potential respondents, including at least 1 attempt after 5:00 pm local time or on the weekend. If the interviewer still was unable to reach the family member after 3 attempts, the VEC mailed a printed survey along with a cover letter and a prepaid return envelope.
Covariates
We used demographic variables to adjust for factors that are known to affect BFS scores. 28, 29 These variables included the veteran's age, sex, and race/ethnicity as well as the relationship between the BFS respondent and the veteran. We also controlled for the site of death (inpatient hospice/palliative care unit vs all other sites). Demographic and clinical variables were derived from the VA's Corporate Data Warehouse (http://www.hsrd.research. va.gov/for_researchers/vinci/cdw.cfm).
Statistical Analysis
We used frequencies to describe the sample. To examine differences in BFS-PM and Respectful Care and Communication factor scores for decedents treated with and without an episode of aggressive care, we used logistic regression (BFS-PM) or linear regression (Respectful Care and Communication factor) clustered by facility, and adjusted for patient age, sex, race/ethnicity, site of death, and relationship to the BFS respondent. Less than 2% of cases had any missing data. To minimize missing data, we used hot-deck imputation procedures for all multivariate analyses, in which values of missing items were imputed through the random selection of values from a donor pool containing complete information. 30 We chose to use hotdeck imputation instead of other multiple imputation procedures because this method has the following advantages: 1) it provides a single complete data set that is consistent across all analyses/tables in the current study; 2) it imputes only plausible values, thereby requiring no recoding; and 3) it makes fewer distributional assumptions compared with other methods. 31 Stata statistical software (version 13.1; StataCorp LLC, College Station, Tex) was used for all statistical analyses.
We examined whether the effects of aggressive care varied by whether veterans did or did not die in a hospice/ palliative care unit by adding an interaction term between death in a VA inpatient hospice/palliative care unit and the outcomes of interest in all models. The interaction was found to be statistically significant only in the models examining the BFS-PM and the independent variables of "2 acute inpatient admissions" and "any episode of aggressive care." Predicted probabilities (for analyses including the interaction term) or adjusted scores were calculated for all models to show outcome differences by the presence or absence of aggressive care, and to examine the interaction effect for the 2 outcomes. For adjusted predicted probabilities, other covariates were fixed at the overall sample mean value.
Finally, we compared the rates of aggressive care between younger (age < 65 years) and older (age 65 years) patients using bivariate logistic regression. We also ran the (above) multivariate models stratified by the younger and older age groups to examine whether the coefficients and their 95% confidence intervals (95% CIs) for the independent variables of interest differed substantially.
RESULTS
We identified 4957 patients with NSCLC who died during the study period (Fig. 1 ). Of these, 1548 veterans (31.2%) died in an inpatient VA facility and were eligible for the BFS. A total of 190 decedents (12.3%) were excluded because they received care in a VA facility <24 hours before death (37 individuals) or had incomplete or inaccurate contact information for next of kin (153 individuals). A total of 511 next of kin did not respond to the survey, leaving a final sample of 847 veterans with completed BFS scores (62% response rate). Table 1 describes the characteristics and sites of death of the study sample. Nearly all patients were men (98.4%), 72% were white, and approximately one-third were aged < 65 years. Nearly 50% of the patients died in a VA inpatient hospice/palliative care unit. Veterans experiencing 1 episodes of aggressive care were more likely to be younger and to have died in a site other than a hospice/ palliative care unit. However, our bivariate analyses demonstrated no significant differences in rates of aggressive care when age groups were categorized as younger (aged < 65 years) and older (aged 65 years) veterans (results not shown). Approximately two-thirds of the decedents had had at least 2 acute hospital admissions within the last 30 days of life. Approximately 25% of decedents were admitted to an ICU within the last 30 days of life. Chemotherapy administration also was common in the last 30 days of life, occurring in 30.6% of the study sample. Overall, 72% of veterans received at least 1 of these types of aggressive care in the last 30 days of life (Table 2) .
In unadjusted outcome analyses (Table 3) , mean BFS-PM scores were found to be lower for veterans who experienced any aggressive care compared with those who did not (55.7% vs 67.6%; P 5 .002). Similarly, mean Respectful Care and Communication factor scores were lower for decedents who experienced 1 episodes of aggressive care compared with those who experienced no aggressive care episodes (13.0 vs 13.8; P<.001). Similar results for both outcomes were noted for the receipt of intravenous chemotherapy and for veterans with 2 acute care admissions. Table 4 presents the adjusted analyses for the association between aggressive care at 30 days and BFS-PM scores, including the predictive probabilities for "2 acute inpatient admissions" and "any episode of aggressive care." When veterans received chemotherapy within the last 30 days before death, their BFS-PM scores were found to be significantly lower compared with those of veterans who did not receive chemotherapy (52.1% [95% CI, 46%-58%] vs 62.0% [95% CI, 57%-66%]; P 5 .007).
We noted marked differences for decedents who had 2 inpatient admissions or any episode of aggressive care, but these were noted only for those veterans who died in a Original Article b P values do not perfectly coincide with the 95% CIs because the confidence intervals were generated from the predicted probabilities whereas the P value was taken from the aggressive care estimate of the multivariate model. c A statistically significant interaction was found between death occurring in an inpatient hospice/palliative care unit and the independent variable. Therefore, predictive probabilities for each level of the interaction were presented.
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Cancer VA non-hospice/palliative care inpatient unit. These associations were moderated by whether the veterans died in an inpatient hospice/palliative care unit. For example, if a veteran had received any aggressive care and died in a hospice/palliative care unit, 64% (95% CI, 58%-70%) of respondents rated care as "excellent," whereas only 48.4% (95% CI, 42%-55%) of respondents rated care as "excellent" when the veteran died in other inpatient sites. Table 5 shows the adjusted analyses for the association between aggressive care and Respectful Care and Communication factor scores. There were small but statistically significant differences in scores between the groups; families of veterans who received chemotherapy or who experienced any episode of aggressive care rated the Respectful Care and Communication factor lower than the families of veterans who received no chemotherapy or experienced no aggressive care.
Multivariate model analyses stratified by younger (aged < 65 years) and older (aged 65 years) patients demonstrated no meaningful differences in the associations between independent and dependent variables. Although independent variable estimates varied somewhat across the stratified models, the direction of the results was similar and 95% CIs overlapped substantially (results not shown).
DISCUSSION
The current study examined aggressive care in a national sample of patients with NSCLC who died in a variety of VA inpatient settings. We found that aggressive care is common in these patients. Nearly 75% of patients experienced at least 1 episode of aggressive care within the last month of life. Furthermore, aggressive care generally was associated with lower ratings of the veteran's end-of-life care by bereaved families. Other studies have identified high rates of aggressive care at the end of life. Bekelman et al 1 reported similar rates of ICU admissions within the last 30 days of life (27.2%), although outpatient chemotherapy rates were lower (10.6%). Wright et al 24 reported a chemotherapy rate of just 6.5% in the last 30 days of life and much lower rates of 2 hospitalizations (6.1%) and ICU admissions (13.1%) within the last month. The potential reason for these differences when compared with the current study sample is unclear. One difference that may account for the higher rates noted in the current study is that nearly 34% of the sample herein was aged <65 years. Preferences for more aggressive treatment are associated with younger age. 32 However, we found that the rates of aggressive care among older and younger veterans were not statistically different, and thus age was likely not a major contributor to the higher use of aggressive care observed in the current study. It is possible that 2 other factors played bigger roles. First, the current study sample was limited to veterans who died in an inpatient setting. The fact that these patients died in a medical center presumably reflects a preference for aggressive treatment. Second, higher rates of aggressive care such as chemotherapy may reflect the VA policy of allowing Original Article veterans to receive curative therapies concurrently with end-of-life care. 13 These 2 factors also may have contributed toward the higher rates of aggressive care observed among VA patients in the current study compared with those reported by Keating et al. 11 The current study finding that aggressive care is associated with less favorable patient and family experiences is consistent with earlier studies. 24, 33 The results are in keeping with those of Teno et al, 33 who reported that bereaved families were more likely to rate the quality of care that their loved one experienced as poor if the patients had been admitted to an ICU in the weeks before their death. However, in contrast to the results of Wright et al, 24 we found significant differences in both the overall rating of care and the Respectful Care and Communication factor scores between veterans who did and did not receive injectable chemotherapy shortly before death. This difference may be attributable to sample sizes. Only 6.9% of the patients (75 patients) in the study by Wright et al 24 received chemotherapy within the last 2 weeks of life versus nearly 28% (236 patients) of patients in the current study who received chemotherapy within the last 30 days of life, providing us with greater statistical power to detect differences.
The associations between the overall rating of care and the occurrence of 2 inpatient admissions and any aggressive care were moderated by whether the veterans died in an inpatient hospice/palliative care unit. That is, when veterans died in VA hospice/palliative care units, aggressive care was not associated with lower BFS-PM scores. Other investigators have reported that families' evaluations of end-of-life care are higher for patients who die in inpatient or home hospice settings. [34] [35] [36] However, to the best of our knowledge, the current study is the first to document that care in an inpatient hospice setting may mitigate some of the negative effects of aggressive care on families' perceptions of care.
It is interesting to note that it appears that care in a hospice/palliative care unit did not lessen the slightly more negative views regarding the Respectful Care and Communication factor noted for patients treated with types of aggressive care. Although we did not directly ascertain patient/family preferences for care separately as was done in the study by Wright et al, 24 the Respectful Care and Communication factor herein, that "staff gave treatment that the veteran wanted," is similar to their outcome of "family member reported wishes of the patient were followed." 24 Whereas Wright et al found that hospice care was associated with significantly higher reports that patients' wishes were followed, 24 the results of the current study demonstrated no effect on our similar outcome. It may be that care before the hospice/palliative care inpatient admission was markedly at odds with patient/family preferences for care, and that a family's negative memories of this discordant care were not "erased" by hospice/palliative care. The current study is limited in that the BFS was administered only to bereaved families of veterans who died in VA inpatient settings; this group comprised only 31% of all decedents. Therefore, we were unable to determine the influence of aggressive care on families' perceptions of care for veterans who died at home. The current study sample was restricted to patients diagnosed with late-stage NSCLC and therefore may not be generalizable to patients with other cancers. In addition, as noted, the current study sample was relatively young and predominantly male. However, we attempted to survey all eligible decedents and achieved a high survey response rate (62%). Finally, the current study was conducted at the VA, which serves only military veterans and is unique to the United States. Nonetheless, the VA is the largest integrated health care system in the United States.
The results of the current study add to the literature by documenting the associations between aggressive care at the end of life and families' perceptions of care for decedents who died in inpatient settings within an integrated health care system. Although we were unable to make causal inferences from our analysis, the findings of the current study suggest that aggressive care for seriously ill patients with cancer is not likely to contribute positively to patients' and families' experiences in the final days of life. Furthermore, the current study results support the view that aggressive care is an indicator of poor-quality end-of-life care. Additional research is needed to understand why aggressive care is so common among patients with advanced cancer and how we can improve this endof-life care for patients and their families. 
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